Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Defence Therapeutics

Main (gene editing) focus: Novel methods for delivery of gene-editing systems

Company stage: Pre-clinical

Diseases: Undisclosed

Genome editing tool: CRISPR-Cas9

Funding stage: Public (NASDAQ:DTCFF)

Location: Vancouver, British Columbia, Canada


Defence Therapeutics develops a proprietary platform called ACCUMTM, which enables precision delivery of vaccine antigens or drugs to target cells. The company recently announced strong in vitro results for the delivery of the CRISPR-Cas9 system using ACCUMTM technology. The company now seeks collaborations in the gene-editing space.


HashtagDefence Therapeutics

Company: Defence Therapeutics
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine